IRADIMED CORP
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $83.8M | $73.2M | $65.6M | $53.3M | $41.8M |
| Gross profit | $64.3M | $56.4M | $50.2M | $41.3M | $32.0M |
| Operating income | $26.1M | $22.0M | $20.0M | $15.6M | $9.8M |
| Operating expenses | $38.2M | $34.4M | $30.1M | $25.7M | $22.2M |
| Cost of revenue | $19.5M | $16.9M | $15.4M | $12.0M | $9.8M |
| Cash from operations | $24.9M | $25.6M | $13.5M | $10.0M | $11.3M |
| Capital expenditure | $7.8M | $8.0M | $7.4M | $823,019 | $482,325 |
| Free cash flow | $17.2M | $17.6M | $6.0M | $9.2M | $10.8M |
| Total assets | $108.8M | $98.3M | $92.2M | $85.5M | $82.9M |
| Total liabilities | $14.2M | $11.5M | $20.7M | $11.8M | $10.7M |
Shares outstanding 12.8M · Free float 30.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.